Loading...
XSTO
IVACC
Market cap36mUSD
Jun 10, Last price  
1.03SEK
1D
-3.74%
1Q
7.29%
IPO
-85.16%
Name

Intervacc AB

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
29.78
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.34%
Rev. gr., 5y
-0.59%
Revenues
12m
+47.06%
794,40078,086,67162,830,77655,575,48848,004,13635,600,00012,139,0004,780,0005,241,0009,684,0008,015,00011,787,000
Net income
-76m
L-26.58%
-2,285,0579,323,666138,077-6,806,616-12,766,582-27,492,000-27,892,000-25,601,000-29,375,000-64,158,000-102,852,000-75,515,000
CFO
-53m
L+16.06%
00-19,085,339-4,199,997-19,158,104-4,033,000-2,770,000-20,081,000-25,463,000-69,790,000-45,834,000-53,195,000
Earnings
Aug 27, 2025

Profile

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
URL
http://intervacc.se/
IPO date
Apr 07, 2017
Employees
15
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,787
47.06%
8,015
-17.23%
9,684
84.77%
Cost of revenue
15,314
39,366
47,746
Unusual Expense (Income)
NOPBT
(3,527)
(31,351)
(38,062)
NOPBT Margin
Operating Taxes
11,388
3
Tax Rate
NOPAT
(3,527)
(42,739)
(38,065)
Net income
(75,515)
-26.58%
(102,852)
60.31%
(64,158)
118.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
103,506
6,120
BB yield
-26.82%
-0.41%
Debt
Debt current
39
139
Long-term debt
142
183
Deferred revenue
Other long-term liabilities
106
Net debt
(34,404)
(88,160)
126,955
Cash flow
Cash from operating activities
(53,195)
(45,834)
(69,790)
CAPEX
(706)
(56)
(6,132)
Cash from investing activities
(706)
(2,107)
(6,132)
Cash from financing activities
(36)
90,583
5,909
FCF
(3,191)
(29,275)
(51,669)
Balance
Cash
34,404
88,341
45,699
Long term investments
(172,332)
Excess cash
33,815
87,940
Stockholders' equity
15,147
151,473
(42,888)
Invested Capital
147,288
150,172
293,369
ROIC
ROCE
EV
Common stock shares outstanding
88,280
60,963
57,908
Price
1.17
-81.52%
6.33
-75.65%
26.00
-51.13%
Market cap
103,288
-73.23%
385,896
-74.37%
1,505,609
-51.00%
EV
68,884
297,736
1,632,564
EBITDA
(3,527)
(6,752)
(17,204)
EV/EBITDA
Interest
133
125
Interest/NOPBT